FIGO and WHF Position Paper Guides Menopause Hormone Therapy in Cardiac Risk

This joint FIGO-WHF position paper gives pharmacists a framework for tailoring MHT type, dose, and route in menopausal women with cardiovascular risk factors or established ischemic heart disease.

📅 Journal publication: 2026 (online Sep 22, 2026) · Last updated: Oct 7, 2026

FIGO-WHF Joint Position PaperInternational Federation of Gynecology and ObstetricsWorld Heart Federationmenopause hormone therapyischemic heart diseasecardiovascular risktransdermal estradiolmicronized progesteronedydrogesteronestatins Women's Health

Background Information

Addressing MHT in women with cardiovascular risks for better health management.

The paper addresses the use of menopause hormone therapy (MHT) in women with cardiovascular risks, crucial for managing health in these patients. Systemic MHT started early is beneficial, with transdermal estrogen combined with micronized progesterone or dydrogesterone being safest for high-risk women. The position paper guides the use of MHT in women with cardiovascular risk, emphasizing customized therapy and multidisciplinary care. MHT can be safely used in select women with cardiovascular risks, requiring personalized strategies.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Benedetto C, Gulati M, Khadilkar SS, Maas AHEM, Frezet F, de Oliveira GMM, Genazzani AR, Divakar H, Poppas A, International Federation of Gynecology and Obstetrics (FIGO) and World Heart Federation (WHF)

Citation: Benedetto C, Gulati M, Khadilkar SS, et al. Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper. Global heart. 2026;21(1):67. doi:10.5334/gh.1576

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →